Integumen PLC: Unveiling of new breath test/dig'l health platform

  • Unveiling of new COVID-19 personalised real-time Breath Test and Digital Health Pass Platform
  • COVID-19 wastewater Microtox ready for beta testing
  • Heads of Agreement with Avacta and Aptamer Group for commercial scale supply of SARS-CoV-2 binding agents

YORK, England, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Integumen today announces progress for its COVID-19 wastewater detection system, Microtox PD, in collaboration with Modern Water plc ("Modern Water"), Avacta Group plc ("Avacta") and Aptamer Group Limited ("Aptamer"). The Company also today announces the unveiling of a new personalised COVID-19 breath test, Microtox BT, and its complementary Digital Health Pass platform.

Integumen is working with a consortium of companies collaborating to find solutions in the fight against COVID-19 pandemic. The consortium includes Modern Water, Avacta, Aptamer and a major global provider of innovative technology and services for the data era.

Microtox BT and Digital Health Pass - on the spot triaging of COVID-19 infections offer potential to re-open the economy
Integumen recognised that in collaboration with Modern Water, Avacta and Aptamer Group, its real-time detection and alert system could be adapted to detect the level of infection of coronavirus in a breath sample. Adapting the wastewater test, Microtox PD, the Company has designed, built and tested a prototype, Microtox BT, which can analyse the breath and detect the spike protein of SARS-CoV-2 in real-time for those with a high viral load. Microtox BT has undergone extensive internal testing and will now transition to the University of Aberdeen containment level 3 laboratory, to undergo tests directly on the virus followed by a joint trial of up to 5,000 participants in parallel with third parties using reverse transcription polymerase chain reaction ("rtPCR")[i] and Antigen tests. Results are anticipated before the end of the year and Microtox BT is expected to be a Class 1 medical device[ii].

Click on, or paste the following link into your web browser, to view the associated PDF document.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

AIM share code: SKIN

Back to news